LCL161 is an orally bioavailable SMAC mimetic, potently binds to and inhibits multiple IAPs (i.e. XIAP, c-IAP). LCL161 enhanced the proapoptotic effects of nilotinib and PKC412, against leukemic disease in vitro and potentiated the activity of both kinase inhibitors against leukemic disease in vivo.
Molecular Weight:
500.63
Purity:
99.70%
CAS Number:
[1005342-46-0]
Formula:
C26H33FN4O3S
Target:
IAP
* VAT and and shipping costs not included. Errors and price changes excepted